INTENDED AUDIENCE

Primary care physicians (family physicians, internists, general practitioners) and other healthcare professionals interested in the diagnosis, management, and treatment of benign prostatic hyperplasia/lower urinary tract symptoms, hypogonadism, and erectile dysfunction attending the 2014 American Academy of Family Physicians Scientific Assembly.

STATEMENT OF NEED

As men's life expectancy increases, there is a critical need to address the burgeoning health concerns associated with an aging population, including cardiovascular disease (CVD) that is an increasing cause of morbidity and mortality. It has been established that ED, BPH/LUTS and low testosterone levels are common with aging and studies have investigated the relationship between these comorbid conditions and risk factors for CVD. Therefore, it is critical to examine the relationship between common men's health conditions and CVD and whether morbidity may be decreased with treatment.

Given the close associations between BPH/LUTS, hypogonadism, and ED, treatment algorithms are needed for the concomitant management of LUTS and hypogonadism as well as associated conditions, such as sexual dysfunction, and CVD. An effective management strategy would incorporate pharmacologic agents that are efficacious and tolerable, cause minimal AEs, and can be used either as monotherapy or in a combination regimen as appropriate. Physicians should take into account individual health factors, efficacy, tolerability, treatment-related AEs (eg, retrograde ejaculation, diminished libido, and ED), cost, and patient preference. As evidence accumulates, considering how daily phosphodiesterase type 5 inhibitor therapy may improve erectile function, BPH/LUTS and cardiometabolic parameters and how treatment of hypogonadism with testosterone therapy affects BPH/LUTS, ED, as well as metabolic syndrome components may open new research avenues and shift the current treatment paradigm.

EDUCATIONAL OBJECTIVES

1. Screen all men seeking care for hypogonadism, benign prostatic hyperplasia–associated lower urinary tract symptoms (BPH/LUTS), and erectile dysfunction (ED) for related comorbidities
2. Recognize hypogonadism and ED may be early indicators of metabolic syndrome, which predicts serious endothelial dysfunction and cardiovascular disease
3. Examine with patients the adverse effect (AE) profile of each therapy when deciding the appropriate management strategy for hypogonadism, BPH/LUTS, or ED and carefully monitor the patient's treatment response
4. Select therapeutic modalities with minimal AEs, including sexual AEs
5. Monitor the effects of treatment for BPH/LUTS, hypogonadism, or ED on the prostate and metabolic syndrome components
6. Integrate hypogonadism, BPH/LUTS, and ED treatment goals to improve quality of life and optimize health outcomes for all men

ACCREDITATION AND CERTIFICATION

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CogniMed Inc and Dannemiller. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.

Dannemiller designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

Approved for 1.25 AAFP Prescribed credit(s). This live activity, The Primary Perspective: Bridging Gaps in Male Urologic and Cardiovascular Health with a begin date of October 22, 2014, has been reviewed and is acceptable for up to1.25 (Prescribed/Elective) credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provided by

This event is not part of the official AAFP Scientific Assembly.

This activity is supported by an independent educational grant provided by Lilly USA, LLC.